Amarin Corp Plc (AMRN)

[Tal10]

A caption from a Medpage Today article from 2016:

"The FDA downplays the larger significance of the settlement but many observers see the start of a major shift away from strict FDA regulation of drugs. "This is a horrible precedent," said Steve Nissen, MD, of the Cleveland Clinic. "Off-label promotion of drugs isn't about freedom of speech, it's about misleading physicians and patients about the benefits and risks of treatments. 'Truthful' promotion of icosapent ethyl [Vascepa] would require Amarin to state that the drug has no proven benefits in patients with moderately elevated triglycerides." (Nissen disclosed that he is chairing a large 13,000 patient trial with a different fish oil drug, Epanova.)"